Top Page
Fiji Kava Limited
(Sydney:CCO)
Fiji Kava Limited (CCO) vs. iShares MSCI Australia ETF (EWA)
Fiji Kava Limited Business Overview & Revenue Model
Fiji Kava Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.03M | 8.03M | 4.26M | 1.78M | 2.05M | 1.16M |
| Gross Profit | 3.48M | 3.48M | 2.05M | -1.40M | 236.14K | 404.43K |
| EBITDA | -3.49M | -3.45M | -3.34M | -4.86M | -5.72M | -3.19M |
| Net Income | -3.99M | -3.99M | -3.73M | -5.24M | -5.92M | -3.39M |
Balance Sheet | ||||||
| Total Assets | 5.68M | 5.68M | 4.33M | 3.24M | 4.79M | 3.60M |
| Cash, Cash Equivalents and Short-Term Investments | 1.46M | 1.46M | 1.10M | 462.15K | 814.06K | 1.18M |
| Total Debt | 2.31M | 2.31M | 2.21M | 2.35M | 1.78M | 267.12K |
| Total Liabilities | 3.78M | 3.78M | 4.80M | 3.32M | 2.51M | 694.78K |
| Stockholders Equity | 1.90M | 1.90M | -466.84K | -87.53K | 2.28M | 2.91M |
Cash Flow | ||||||
| Free Cash Flow | -4.83M | -4.83M | -2.19M | -3.82M | -7.10M | -4.40M |
| Operating Cash Flow | -4.37M | -4.37M | -2.08M | -3.80M | -6.14M | -4.14M |
| Investing Cash Flow | -459.91K | -459.91K | -116.97K | -21.08K | -964.94K | -259.37K |
| Financing Cash Flow | 5.19M | 5.19M | 2.83M | 3.47M | 6.74M | 4.16M |
Fiji Kava Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
43 Neutral | ― | ― | ― | ― | ― | 27.69% | |
42 Neutral | AU$9.43M | -2.78 | -77.48% | ― | 63.30% | 70.00% | |
41 Neutral | AU$6.84M | -2.02 | -60.84% | ― | -18.70% | 20.83% | |
37 Underperform | AU$12.23M | ― | -555.97% | ― | 88.48% | 51.61% | |
31 Underperform | AU$4.50M | -0.64 | ― | ― | -21.84% | 79.99% |
Fiji Kava Limited Corporate Events
The Calmer Co. International Limited announced that all resolutions proposed at its Annual General Meeting were passed by the required majority, marking a successful outcome for the company. This development is likely to positively impact the company’s operations and reinforce its strategic positioning in the market for natural relaxation and sleep support products, benefiting stakeholders by potentially enhancing growth and market reach.
The Calmer Co International Limited has announced the resignation of John Homewood from its board of directors, effective November 7, 2025. This change in leadership could potentially impact the company’s strategic direction and stakeholder relations, given Homewood’s significant holdings in the company through Homewood Venture Capital Pty Ltd and Ace Property Holdings Pty Ltd.
The Calmer Co International Limited has announced the issuance of 700,000 unquoted convertible notes, as part of a previously announced transaction. This move is part of the company’s strategic financial maneuvers, potentially impacting its market positioning and signaling a shift in its capital structure.
The Calmer Co International Limited has announced its upcoming Annual General Meeting (AGM), scheduled to take place on November 28, 2025, at the offices of HWL Ebsworth Lawyers in Brisbane, Queensland. The agenda includes the presentation of the annual financial report, consideration of the Remuneration Report, and the re-election of Dr. Anthony Noble as a director. Shareholders are encouraged to participate and vote on the resolutions presented, although the vote on the Remuneration Report is advisory and non-binding.
Fiji Kava Limited has reported exceptional sales momentum in the first quarter of 2026, with significant growth across all channels. The company has streamlined its business model, resulting in strong global sales growth and reduced costs, which is moving the company closer to achieving break-even. In Australia, revenue increased by 30% due to higher orders from major retailers Coles and Woolworths, while U.S. sales grew by 20% following the launch of new flavored kava shots. The expansion of partnerships, such as with IMCD Network Nutrition, has also contributed to a 20% rise in wholesale and distribution sales.
The Calmer Co. International Limited, operating in the wellness industry, focuses on diversified sales channels including retail, e-commerce, and wholesale, with a strong presence in Australia and the United States. The company, known for its kava extracts, is strategically positioned for growth with secured funding and a focus on high-value B2B channels. In its latest quarterly report, The Calmer Co. announced record revenue of $2.4 million, marking a 26% increase quarter-on-quarter, and the lowest net operating cash outflows in its history. The company attributes this success to disciplined cost management and strategic partnerships, particularly in the Australian retail sector and through new product launches on Amazon USA. The secured convertible note funding and inventory expansion are set to support further growth initiatives, highlighting the company’s strong market positioning and potential for breakeven in FY26.
The Calmer Co International Limited has announced a change in the director’s interest notice, specifically involving Zane Yoshida. The announcement details the acquisition of 20 million fully paid ordinary shares (FPOS) by UMI7 Investments Pty Ltd, where Mr. Yoshida holds an indirect interest as a director and beneficiary. This move reflects an increase in the director’s indirect holdings, potentially strengthening his influence and stake in the company.
The Calmer Co. International Limited has issued 47 million fully paid ordinary shares as part of its share plan, without requiring disclosure to investors under specific provisions of the Corporations Act 2001. This strategic move, authorized by the company’s Board of Directors, aligns with regulatory compliance and suggests a potential strengthening of the company’s financial position, impacting its market operations and stakeholder interests.
The Calmer Co International Limited, identified by the ASX issuer code CCO, has announced the quotation of 47,000,000 ordinary fully paid securities on the Australian Securities Exchange (ASX). These securities, issued under an employee incentive scheme, are set to be quoted despite any transfer restrictions, potentially enhancing the company’s market liquidity and investor appeal.
Fiji Kava Limited has reported significant financial growth with $8 million in revenue for FY25, marking an 86% year-over-year increase and nearly fivefold growth over two years. The company is on track to achieve breakeven by 2026, highlighting its strong positioning and potential impact in the kava industry.
The Calmer Co. International Limited has announced a record-breaking quarterly revenue of $2.4 million for the first quarter of FY26, marking a 26% increase from the previous quarter. This growth is driven by strong sales in Australia and the USA, with significant contributions from retail distribution and new product launches on Amazon. The company has also secured $700,000 as part of a convertible note issuance to bolster inventory and growth initiatives, positioning it well to achieve breakeven. The company’s diversified sales and marketing strategies, along with its expanding B2B business, underscore its potential in the global kava market.
The Calmer Co International Limited has announced a proposed issue of 1,400,000 convertible notes, with the issuance date set for September 30, 2025. This move is part of a placement or other type of issue, and the company has applied for these securities to be quoted on the ASX, pending approval. This issuance is expected to impact the company’s financial operations by potentially increasing its capital base, which could enhance its market positioning and provide new opportunities for stakeholders.
The Calmer Co. International Limited has secured $1.4 million through a convertible note raise, with the first tranche of $700,000 already committed. This funding will be used to build inventory and support working capital as the company continues its growth trajectory, particularly in the US market where it has seen a 21% increase in revenue. The involvement of Applied Food Sciences as a strategic investor underscores confidence in The Calmer Co.’s expansion strategy, especially in the wholesale channel, and aligns with its goal of building a global platform for its nutraceutical business.